http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Si Mong Yoon ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Longitudinal Clinical Course of Preserved Ratio Impaired Spirometry Compared to COPD
( Si Mong Yoon ),( Hyun Woo Lee ),( Eun Young Heo ),( Deog Kyeom Kim ),( Jung-kyu Lee ) 대한결핵 및 호흡기학회 2021 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.129 No.-
Background Preserved ratio impaired spirometry (PRISm) is a heterogeneous disease entity, and limited data are available about the prevalence, trajectories and prognosis of PRISm. We assessed the longitudinal clinical course of patients with PRISm compared to chronic obstructive pulmonary disease (COPD). Methods A retrospective study was conducted between January 2013 and December 2020 on PRISm and COPD patients who underwent chest CT imaging and longitudinal pulmonary function tests. We evaluated differences of acute exacerbation history and lung function changes between PRISm and COPD. Results Of the 716 patients, 45 and 671 patients had PRISm and COPD, respectively. PRISm patients had younger age, less smoking history, lower Charlson comorbidity index, and more history of tuberculosis and physician-diagnosed asthma, compared to COPD patients. PRISm did not differ significantly from COPD in the risk of acute exacerbation during longitudinal follow-up. PRISm patients show significant lower rates of FEV1 and FVC decline despite of lower baseline FVC, than COPD patients. Conclusion PRISm patients had no significant difference in risk of acute exacerbation, but significant slower decline of lung function during longitudinal follow-up, compared to COPD patients.
-
( Jeong Heo ),( Yoon Jun Kim ),( Jin-woo Lee ),( Ji Hoon Kim ),( Young-suk Lim ),( Kwang-hyub Han ),( Sook-hyang Jeong ),( Mong Cho ),( Ki Tae Yoon ),( Si Hyun Bae ),( Eric D. Crown ),( Linda M. Fredr 대한간학회 2021 Gut and Liver Vol.15 No.6
Background/Aims: Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antivi ral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy and safety of G/P in Korean patients with chronic hepatitis C virus (HCV) infection. Methods: The study analyzed pooled data on Korean patients with HCV infection enrolled in the ENDURANCE 1 and 2, SURVEYOR II part 4 and VOYAGE I and II trials, which evaluated the efficacy and safety of 8 or 12 weeks of G/P treatment. The patients were either treatment-naïve or had received sofosbuvir or interferon-based treatment. Efficacy was evaluated by assessing the rate of sustained virologic response at 12 weeks posttreatment (SVR12). Safety was evaluated by monitoring adverse events (AEs) and laboratory assessments. Results: The analysis included 265 patients; 179 (67.5%) were HCV treatment-naïve, and most patients were either subgenotype 1B (48.7%) or 2A (44.5%). In the intention-to-treat population, 262 patients (98.9%) achieved SVR12. Three patients did not achieve SVR12: one had virologic failure and two had non-virologic failures. Most AEs were grade 1/2; eight patients (3.0%) expe rienced at least one grade ≥3 AE. No serious AEs related to G/P treatment were reported, and grade ≥3 hepatic laboratory abnormalities were rare (0.8%). Conclusions: G/P therapy was highly efficacious and well tolerated in Korean patients with HCV infection, with most patients achieving SVR12. The safety profile was comparable to that ob served in a pooled analysis of a global pan-genotypic population of patients with HCV infection who received G/P. (Gut Liver 2021;15:895-903)
KCI연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
